Glen Eagle Advisors, LLC Krystal Biotech, Inc. Transaction History
Glen Eagle Advisors, LLC
- $546 Billion
- Q2 2024
A detailed history of Glen Eagle Advisors, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 5 shares of KRYS stock, worth $927. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5Holding current value
$927% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding KRYS
# of Institutions
281Shares Held
24.8MCall Options Held
270KPut Options Held
177K-
Black Rock Inc. New York, NY3.95MShares$732 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.87MShares$532 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.43MShares$451 Million6.1% of portfolio
-
State Street Corp Boston, MA1.33MShares$247 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA1.02MShares$189 Million12.22% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.76B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...